Clinical Trial

MInimal Residual Disease Adapted Strategy

Study acronym: MIDAS
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
IFM 2020-02 will enroll patients eligible for ASCT less than 66 years. All patients will receive induction based on 6 cycles (28-day) of KRD-Isatuximab (Isa-KRD), in order to achieve deep responses and high MRD negativity rates. Patients will be classified at diagnosis according to cytogenetics (standard vs high-risk cytogenetics defined by the LP score including 17p deletion, t(4;14), del(1p32), gain 1q, trisomy 21 and trisomy 5).
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2021-06-21; most recent amendment 2024-11-05.
Status change: Recruiting → Active, Not Recruiting 2023-12-06
Status change: Not Yet Recruiting → Recruiting 2022-03-28
Trial Details
NCT Number NCT04934475
Lead Sponsor Intergroupe Francophone du Myelome
Collaborators: Amgen, Sanofi, Bristol-Myers Squibb
Conditions Multiple Myeloma
Enrollment 791 participants
Start Date 2021-12-08
Primary Completion 2024-09-30 (estimated)
Study Completion 2028-09-30 (estimated)
Updated on ClinicalTrials.gov 2024-11-07